Navamedic ASA: Double Digit Growth in the 3rd Quarter, 2025
Navamedic ASA (OSE: NAVA), a Nordic pharma company, reported a 12.9% increase in revenues to NOK 138.9 million in the third quarter of 2025.
The company's gross margin improved to 37.5%, compared to 37.1% in Q3 2024, and Adjusted EBITDA amounted to NOK 11.3 million, up from NOK 8.6 million in 2024.
- Revenues: NOK 138.9 million, a 12.9% increase from Q3 2024
- Gross margin: 37.5%, compared to 37.1% in Q3 2024
- Adjusted EBITDA: NOK 11.3 million, compared to NOK 8.6 million in 2024
No direct quote available in the text.
Author's summary: Navamedic ASA reports double-digit growth in Q3 2025.
More News
- The ECHR: legal and political fault lines
- Calendar Pick: Día de los Muertos - Flagpole
- MLB: Last time each team won the World Series
- Write for Rights Activist Toolkit 2025
- Mike Brown is quickly reaching a crushing realization Knicks fans already knew
- The Salvation Army kicks off 'Coats for Kids' drive with free coat distribution
- 2025 Victoria Derby Field & Betting Update: All Eyes on Observer - races.com.au
- 2026 Škoda Kodiaq: Plug-in hybrid added to popular large SUV range
- Reneé Rapp Is Officially Heading Down Under Next Year - Star Observer
- Obituaries – Week of Oct. 27, 2025 - The Observer